Revel Pharmaceuticals Inc.
San Francisco, CA Doing business as Revel Pharmaceuticals Inc. Revel Pharmaceuticals
- UEI
- RBFMLGKG8KZ3
- CAGE
- 8GJQ4
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2325 3rd St #214, San Francisco, CA 94107, USA
- Website
- revelpharmaceuticals.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of advanced glycation end product (age)-breaking enzymes as a novel therapy for the treatment of diabetic… | National Eye Institute | $358,065 | |
| An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts - project summary advanced glycation… | National Institute of General Medical Sciences | $693,433 | |
| Development of advanced glycation end product (age)-breaking enzymes as a novel therapy for the treatment of diabetic… | National Institute of Diabetes and Digestive and Kidney Diseases | $647,848 | |
| Development of enzymatic tools for rapid measurement of advanced glycation and lipoxidation end product-protein… | National Institute on Aging | $2,287,712 | |
| Development of enzymatic tools for rapid measurement of advanced glycation end product-protein adducts - project summary… | National Institute on Aging | $277,144 |
About Revel Pharmaceuticals Inc.
Revel Pharmaceuticals Inc. is a for-profit biotechnology company located in San Francisco, California, registered in SAM.gov since October 2019. The company focuses on developing innovative enzymatic solutions for addressing advanced glycation end products (AGEs) and their role in age-related diseases. As a corporate entity, Revel Pharmaceuticals specializes in developing advanced enzyme technologies that can potentially diagnose, measure, and potentially treat various metabolic and age-related conditions through precise molecular interventions.
Through its federal grant awards, Revel Pharmaceuticals has consistently secured project grants from multiple National Institutes of Health (NIH) agencies, including the National Eye Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Aging, and National Institute on Alcohol Abuse and Alcoholism. The company's grant-funded research centers on developing enzymatic tools for detecting and potentially treating advanced glycation end products, with specific focus areas including diabetic retinopathy, diabetic kidney disease, age-related molecular modifications, and alcohol-related protein adduct detection. Their research aims to create rapid, cost-effective enzymatic assays for measuring complex molecular markers, with projects targeting enzyme development for detecting carboxymethyl-lysine (CML), carboxyethyl-lysine (CEL), and acetaldehyde-protein adducts. Each project represents a Phase I Small Business Innovation Research (SBIR) grant, demonstrating Revel Pharmaceuticals' commitment to translating advanced enzymatic research into potential diagnostic and therapeutic applications.
Quick answers
What is Revel Pharmaceuticals Inc.'s UEI?
Revel Pharmaceuticals Inc.'s Unique Entity ID (UEI) in SAM.gov is RBFMLGKG8KZ3.
What is Revel Pharmaceuticals Inc.'s CAGE code?
Revel Pharmaceuticals Inc.'s CAGE code is 8GJQ4.
Where is Revel Pharmaceuticals Inc. located?
Revel Pharmaceuticals Inc.'s physical address in SAM.gov is 2325 3rd St #214, San Francisco, CA 94107, USA.
Is Revel Pharmaceuticals Inc. registered in SAM.gov?
Yes. Revel Pharmaceuticals Inc.'s SAM.gov registration is active through January 21, 2027.
What is Revel Pharmaceuticals Inc.'s most recent federal award?
Revel Pharmaceuticals Inc.'s most recent federal grant award is Development of advanced glycation end product (age)-breaking enzymes as a novel therapy for the treatment of diabetic… (R43EY036695), from National Eye Institute, on August 1, 2025.
On GovTribe
See Revel Pharmaceuticals Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors